Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by barsaxon Mar 18, 2020 9:13am

214 Views

Post# 30820753

RE:Abstract Up

...for the record....when RVX discloses the results next Thursday, I'm expecting relative eGFR improvement in the RVX 208 treated patients within the CKD cohort. Very little relative eGFR improvement in the non-CKD cohort. We should get near immediate separation in the performance graphs between the treated CKD group and the control arm of the CKD group.

Bullboard Posts

Calibre discovers significant gold in Newfoundland